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Purpose: The purpose of this study was to compare the surface dose of 7-field IMRT (7 F-IMRT), tangential beam
IMRT (TB-IMRT), and tangential beam 3D-CRT (3D-CRT) of breast cancer patients receiving adjuvant radiotherapy by
means of in vivo GafChromic film dosimetry.
Material and methods: Breast cancer patients receiving adjuvant radiotherapy of the whole breast or the chest
wall were eligible for the study. Study patients were treated with a treatment plan using two different radiotherapy
techniques (first patient series, 3D-CRT followed by TB-IMRT; second patient series, TB-IMRT followed by 7 F-IMRT).
The surface dose was evaluated on three consecutive treatment fractions per radiotherapy technique using in vivo
GafChromic film dosimetry. The paired t-test was used to assess the difference of in vivo GafChromic film readings
or calculated plan parameters of the compared pairs of radiation techniques for statistical significance.
Results: Forty-five unselected breast cancer patients were analysed in this study. 7 F-IMRT significantly reduced the
surface dose compared to TB-IMRT. Differences were greatest in the central and lateral breast or chest wall region
and amounted to a dose reduction of -11.8% to -18.8%. No significant difference of the surface dose was observed
between TB-IMRT and 3D-CRT. A corresponding observation was obtained for the calculated skin dose derived from
dose-volume histograms.
Conclusions: In adjuvant breast cancer radiotherapy, 7 F-IMRT offers a significantly reduced surface dose compared
to TB-IMRT or 3D-CRT.
Keywords: Breast cancer, Intensity modulated radiotherapy, In vivo dosimetry, Surface doseIntroduction
Breast cancer is the most common cancer in females
worldwide [1]. The majority of the patients will receive
adjuvant radiotherapy after breast cancer surgery. The
adjuvant radiotherapy after breast conserving surgery as
well as the adjuvant radiotherapy after mastectomy of
high risk patients have been shown to significantly im-
prove local control and long-term survival [2,3].
Breast cancer radiotherapy is associated with acute
and late radiation effects most importantly of the skin,* Correspondence: VRudat@saadmedical.com
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unless otherwise stated.heart and lung. Intensity modulated radiotherapy (IMRT)
has the potential to improve dose homogeneity and con-
formity of a radiotherapy of the breast or chest wall
thereby reducing side-effects [4-7]. Concerning skin tox-
icity, several studies have reported clinical benefit for
IMRT of the breast [8-12]. The surface dose is of great
relevance in breast cancer radiotherapy because it may
have an impact on acute and late skin toxicity, cosmetic
outcome and local control.
The purpose of this study was to compare the surface
dose of 7-field IMRT (7 F-IMRT), tangential beam IMRT
(TB-IMRT), and tangential beam 3D-conformal radiother-
apy (3D-CRT) of breast cancer patients after breast con-
serving surgery or mastectomy by means of in vivotd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 PTV, fractionation regimen, radiotherapy technique and timing of the in vivo Gafchromic film dosimetry
RT technique 1 RT technique 2 In vivo FD
PTV n/p D/f (Gy) n/f RT technique Fraction number RT technique Fraction number Fraction number
Patient series 1: 3D-CRT versus TB-IMRT
Whole breast 17 (7) 1.80 28 3DCRT 1-25 TB-IMRT 26-28 23-28
Whole breast 1 (1) 2.67 15 3DCRT 1-12 TB-IMRT 13-15 10-15
Chest wall 14 (7) 2.00 25 3DCRT 1-22 TB-IMRT 23-25 20-25
Patient series 2: TB-IMRT versus 7 F-IMRT
Whole breast 7 (0) 1.80 28 TB-IMRT 1-25 7 F-IMRT 26-28 23-28
Whole breast 1 (0) 2.67 15 TB-IMRT 1-12 7 F-IMRT 13-15 10-15
Chest wall 5 (4) 2.00 25 TB-IMRT 1-22 7 F-IMRT 23-25 20-25
Abbreviations: PTV planning target volume, n/p Total number of patients (number of patients with left-sided breast cancer), D/f (Gy) Dose per fraction (Gy), n/f
Number of fractions, RT technique Radiotherapy technique, In vivo FD In vivo Gafchromic film dosimetry, 3D-CRT Conformal 3-dimensional radiotherapy, TB-IMRT






Figure 1 Illustration of the OAR skin and the position of the
in vivo Gafchromic dosimetry films using the image of a 7 F-IMRT
plan in the isocenter plane. The OAR skin was defined as a 3 mm
strip from the surface of the skin to the PTV. PTV for the IMRT plans
included the same PTV used for the 3D-CRT plans plus an extension
into the air anteriorly of the skin of 1.5 cm to ensure appropriate
opening of the 160 MLC Multileaf Collimator. The numbers denote
the position of the in vivo Gafchromic dosimetry films (1 = lateral
position, 2 = central position, 3 =medial position).
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imetry was chosen because calculation of the superficial
dose derived by treatment planning systems are known to
be inaccurate in regions of electronic disequilibrium like
the build-up region [13], and GafChromic films have been
shown to be accurate and useful dosimetric tools for qual-
ity assurance in radiation therapy [14,15].
The superficial dose can be affected by multiple factors
associated with the field arrangement like the source-
surface-distance, field size, angle of incidence and wedges.
In order to specifically evaluate the impact of the radiation
technique on the superficial dose and to minimize the im-
pact of other possible influencing factors, patients of this
study were treated with a treatment plan using two differ-
ent radiotherapy techniques, and in vivo GafChromic film
dosimetric measurements were obtained from the two
radiotherapy techniques used in the same patient.
Methods
Patients with histologically confirmed breast cancer re-
ceiving adjuvant radiotherapy of the whole breast or the
chest wall were eligible for the study. The primary goal
of this study was to compare the surface dose produced
by 7 F-IMRT, TB-IMRT, and 3D-CRT by means of
in vivo GafChromic film dosimetry. The secondary goal
was to compare calculated parameters of the dose distri-
bution of the corresponding treatment plans.
For all patients, a treatment plan using two radiother-
apy techniques was generated prior to radiotherapy.
Radiotherapy technique 1 was applied for all radiother-
apy fractions except for the last three radiotherapy frac-
tions where radiotherapy technique 2 was applied. In
vivo GafChromic film dosimetry measurements were per-
formed during the last six radiotherapy fractions (three frac-
tions technique 1 and three fractions technique 2). In the
first series of patients, radiotherapy technique 1 and 2 con-
sisted of 3D-CRT and TB-IMRT. In a second series of pa-
tients, TB-IMRT and 7 F-IMRT were used as radiotherapytechnique 1 and 2. Table 1 demonstrates the prescribed frac-
tionation regimen, treatment techniques and the timing of
the in vivo GafChromic film dosimetry measurements.
The target volumes were defined and the dose pre-
scribed according to the International Commission on
Radiation Units and Measurement (ICRU) Reports 50
and 62 recommendations. Accordingly, the target vol-
ume should be surrounded by the 95% isodose line of
the prescribed dose. The planning target volume (PTV)
definition for the whole breast or chest wall was done
according to the recommendations of the breast cancer
atlas for radiation therapy planning consensus defini-
tions of the Radiation Therapy Oncology Group (RTOG)
[16]. The PTV of the breast included the apparent com-
puted tomography (CT) glandular breast tissue and the
PTV of the chest wall the pectoralis muscle, chest wall
0 50 100 150 200 250 300 350 400
















Figure 2 EBT3 film calibration curve.
Figure 3 Illustration of the beam configuration used for 3D-CRT
and TB-IMRT (A) and 7 F-IMRT (B).
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3 mm from the superficial skin surface. The volume of
outermost 3 mm from the superficial skin surface to the
PTV was contoured as organ at risk (OAR) and labeled
“skin” (Figure 1). The heart was defined as all visible
myocardium, from the apex to the right auricle, atrium,
and infundibulum of the ventricle. The pulmonary trunk,
root of the ascending aorta, and superior vena cava were
excluded. Other contoured structures included the ipsilat-
eral and contralateral lung, the contralateral breast, the
esophagus and the spinal cord.
The study was approved by the local Institutional Re-
view Board and Ethics committee. All patients provided
signed informed consent and the study was conducted
in accordance with the ethical standards of the Helsinki
Declaration of 1975, as revised in 2000. For the statis-
tical analysis, the patient data were anonymized to guar-
antee privacy.
In vivo GafChromic film dosimetry
In vivo dosimetry was performed using GafChromic EBT3
films (International Specialty Products, Wayne, New Jersey,
USA). For calibration, ten 4 × 10 cm2 EBT3 filmstrips
(lot # A05151202) were irradiated using the 6 MV pho-
ton beam of a Siemens Oncor Anvantgarde linear ac-
celerator with a 160 MLC Multileaf Collimator at the
center of 10 × 10 cm2 field. The films were irradiated
at a depth of 10 cm and 90 cm source-surface distance
(SSD) in a water-equivalent material phantom (PTW,
Germany). Calibration film doses (0.0 Gy, 0.1 Gy, 0.3 Gy,
0.5 Gy, 0.7 Gy, 1 Gy, 1.5 Gy, 2.0 Gy, 2.5 Gy, 3.0 Gy, and
3.5 Gy) were calibrated against the ion chamber (Farmer
chamber, 0.6 cc) measurement at the same location and
depth. The output of the Oncor Anvantgarde linear accel-
erator was calibrated as per IAEA-TRS 398 protocol.
Forty-eight hours after exposure, the ten calibration filmsplus an unexposed film from the same lot were scanned
using a Vidar DosimetryPRO Advantage (Red) scanner
(3D Systems Corporation, USA), read with Mephysto mc2
1.6 (PTW, Germany) software, and optic density-dose
calibration curves were obtained (Figure 2). Based on the
calibration data, the film dose of the in vivo Gafchromic
dosimetry films was estimated using the patient plan veri-
fication software VeriSoft (PTW, Germany).
Table 2 Dose-volume constraints for IMRT plans
Structure Type Rank Objective Dose
(cGy)
Volume (%) Weight
PTV Target 1 Maximum 5200 0 100










2 Minimum 1200 30 100
Heart Organ
at risk





4 Maximum 4500 0 100
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were carefully placed at three defined positions on the
skin of the treated breast or chest wall. One film was
placed at the central beam axis (“central”), the two other
films 2 cm inside the medial and lateral treatment field
borders (Figure 1). Films were scanned 48 hours after ir-
radiation. For the dose estimation, ten point dose mea-
surements were performed on a region of interest (ROI)
of 2.5 × 2.5 cm2 and the mean dose calculated. Nine of
the ten point dose measurements were performed at de-
fined equally distributed positions and one in a random
position. Dose readings were given as percent of the pre-
scribed dose for all calculations.
The time interval of 48 hours between exposure and
measurement of the calibration films and the in vivo
dosimetry films was chosen because variations in net op-
tical density have been shown to be negligible at thisFigure 4 Comparison of two radiotherapy plans of the same patient.
lines represent the 95% isodose lines, and the red line the 90% isodose linepostirradiation development time [17], and because the
time interval of 48 hours is convenient in the clinical
setting considering the weekend.
Treatment planning
A non-contrast CT-simulation was performed in the su-
pine position on a carbon breast board with the ipsilat-
eral arm up and head turned to the contralateral side.
Radio-opaque wires were used to mark the clinical
boundaries. A CT scan was performed using 5 mm slice
thickness. The CT scanning reference point was defined
using the CT simulation software Coherence Dosimetrist
(Siemens Medical), and target volumes (PTV and OARs)
using the software Coherence Oncologist (Siemens
Medical). The 3D-CRT and IMRT plans were generated
using the treatment planning system XIO 4.4 (CMS, Inc.
of St. Louis, Mo, USA). A Siemens Oncor Anvantgarde
linear accelerator with a 160 MLC Multileaf Collimator
was used for the treatment. The leaf width was 0.5 cm at
the isocenter. The dose calculation was determined using
the “Superposition” algorithm. The beam energy of 6 MV
was used for all 3D-CRT and IMRT plans.
Dose volume histograms (DVH) of the PTV and OARs
of the 3D-CRT and IMRT plans were generated and
dose parameters compared. The OAR “skin” was defined
as the volume of outermost 3 mm from the superficial
skin surface to the PTV (Figure 1) and the “skin dose” as
the calculated mean dose of the whole volume.
The Homogeneity index (HI) was defined as the fraction
of the PTV with a dose between 95% and 105% of the pre-
scribed dose. The Conformity Index (CI) was defined as(A), 3D-CRT versus TB-IMRT; (B), TB-IMRT versus 7 F-IMRT. The yellow
s.
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(V95%) multiplied by the fraction of the total body volume
covered by the reference PTV dose ((PTV95%/PTV) ×
(PTV95%/V95%)) [18].
3D-CRT plans
The dose was prescribed to the ICRU reference point
which was usually the isocenter located in the PTV volume
centroid. Two tangential semi-opposed beams (to avoid di-
vergence), physical wedges (usually 15° or 30°), a 160 MLC
Multileaf Collimator, and 6 MV photons were used for
3D-CRT. The beam angles, wedge angles, and beam
weighting (usually minimal) were chosen to optimize
coverage of the PTV, while minimizing exposure to the
ipsilateral lung, heart and contralateral breast. Gantry
angles ranged from 42° to 55° for the medial fields and
from 224° to 232° for the lateral fields for patients
treated on the right side, and from 305° to 322° for the
medial fields and from 133° to 147° for the lateral fields
for patients treated on the left side (Figure 3).Table 3 Surface dose by means of in vivo Gafchromic film do




PTV Mean SD Mea
Patient series 1: 3D-CRT versus TB-IMRT
Whole breast
3D-CRT 53.8 6.0 42.
TB-IMRT 53.4 5.4 41.
Difference (%) −0.7 −2.
p-value* n.s. n.
Chest wall
3D-CRT 58.1 5.7 47.
TB-IMRT 58.3 6.3 45.
Difference (%) 0.3 −3.
p-value* n.s. n.
Patient series 2: TB-IMRT versus 7 F-IMRT
Whole breast
TB-IMRT 54.0 3.9 45.
7 F-IMRT 45.6 2.3 43.
Difference (%) −15.6 −3.
p-value* <0.01 n.
Chest wall
TB-IMRT 60.1 5.3 39.
7 F-IMRT 53.0 5.9 38.
Difference (%) −11.8 −3.
p-value* 0.02 n.
Abbreviations: †Proportion of the prescribed dose (%), SD Standard deviation, *PaireTB-IMRT and 7 F-IMRT plans
The PTV for the IMRT plans included the same PTV
used for the 3D-CRT plans plus an extension into the
air anteriorly of the chest of 1.5 cm to ensure appropriate
opening of the 160 MLC Multileaf Collimator (Figure 1).
Inverse treatment planning and 6MV photons were used
for all IMRT plans. The dose was prescribed to the PTV,
and as initial dose volume constraints the IMRT prescrip-
tion table provided by the XIO treatment planning system
was used (Table 2). The IMRT plans were optimized to
cover the PTV and spare the surrounding tissues as much
as possible. A step-and-shoot technique was applied. An
optimization with 100 iterations was then applied, and
followed by a semiautomatic segmentation (minimum
3 cm step size). Segments equal or less than 2 MU were
expelled from the plan. Tissue inhomogeneities were con-
sidered in the treatment planning optimization process,
and the dose calculation algorithm used was “Superpos-
ition”. For the TB-IMRT plan, the same beam orientations
and angles of the corresponding 3D-CRT plan were used.simetry and calculated skin dose in dependence of the
face dose† Calculated skin dose*
position
Medial Lateral
n SD Mean SD Mean SD
2 5.0 48.5 7.1 91.8 13.3
2 6.5 49.1 8.4 90.8 8.7
4 1.2 −1.1
s. n.s. n.s.
2 9.0 49.8 5.1 92.2 6.0
4 7.9 51.9 6.2 92.0 8.8
8 4.2 −0.2
s. n.s. n.s.
0 5.6 41.7 4.5 86.8 6.9
6 7.0 35.8 7.4 80.6 10.8
1 −14.1 −7.1
s. 0.05 0.03
4 12.0 59.2 3.5 95.2 2.3
2 17.6 48.1 8.4 90.5 2.0
0 −18.8 −4.9
s. 0.05 <0.01
d t-test, n.s. not significant, other abbreviations: see Table 1.
Table 4 Relevant plan parameters of 3D-CRT versus TB-IMRT or TB-IMRT versus 7 F-IMRT of the breast or chest wall
Organ Patient series 1: 3D-CRT versus TB-IMRT Patient series 2: TB-IMRT versus 7 F-IMRT
Factor RT technique Mean 95% CI p-value* RT technique Mean 95% CI p-value*
Skin
Mean Dose (percent of the prescribed dose)
3D-CRT 92.0 (88.1; 95.9) n.s. TB-IMRT 90.0 (85.8; 94.2) <0.01
TB-IMRT 91.4 (88.1; 94.8) 7 F-IMRT 84.4 (78.6; 90.3)
Difference (%) −0.7 Difference (%) −6.2
PTV
Homogeneity index
3D-CRT 0.73 (0.65; 0.80) n.s. TB-IMRT 0.75 (0.68; 0.81) n.s.
TB-IMRT 0.73 (0.67; 0.78) 7 F-IMRT 0.72 (0.63; 0.81)
Difference (%) 0 Difference (%) −4.0
Conformity index
3D-CRT 0.76 (0.71; 0.81) <0.001 TB-IMRT 0.88 (0.85; 0.91) n.s.
TB-IMRT 0.86 (0.82; 0.89) 7 F-IMRT 0.88 (0.85; 0.91)
Difference (%) 13.2 Difference (%) 0
Heart (left-sided PTV)
Mean Dose (cGy)
3D-CRT 506 (359; 654) n.s. TB-IMRT 824 (423; 1224) 0.01
TB-IMRT 504 (380; 628) 7 F-IMRT 1647 (937; 2357)
Difference (%) −0.4 Difference (%) 99.9
V70%
3D-CRT 5.12 (2.49; 7.75) 0.03 TB-IMRT 9.25 (1.7; 16.8) n.s.
TB-IMRT 2.57 (1.06; 4.09) 7 F-IMRT 10.00 (1.5; 18.5)
Difference (%) −49.8 Difference (%) 8.1
Heart (right-sided PTV)
Mean Dose (cGy)
3D-CRT 157 (33; 282) n.s. TB-IMRT 78 (60; 97) <0.001
TB-IMRT 149 (42; 282) 7 F-IMRT 704 (603; 805)
Difference (%) −5.1 Difference (%) 802.6
Ipsilateral lung
Mean Dose (cGy)
3D-CRT 1276 (1179; 1374) <0.001 TB-IMRT 1031 (842; 1221) <0.001
TB-IMRT 1036 (943; 1129) 7 F-IMRT 1535 (1382; 1689)
Difference (%) −18.8 Difference (%) 48.9
D60%
3D-CRT 194 (174; 214) n.s. TB-IMRT 139 (101; 177) <0.001
TB-IMRT 187 (168; 206) 7 F-IMRT 686 (458; 913)
Difference (%) −3.6 Difference (%) 393.5
D30%
3D-CRT 1327 (1036; 1618) <0.001 TB-IMRT 934 (535; 1334) <0.001
TB-IMRT 922 (725; 1119) 7 F-IMRT 1775 (1459; 2091)
Difference (%) −30.5 Difference (%) 90.0
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3D-CRT 27 (24; 31) n.s. TB-IMRT 23 (18; 28) <0.001
TB-IMRT 26 (23; 29) 7 F-IMRT 328 (259; 397)
Difference (%) −3.7 Difference (%) 1326.1
Abbreviations: 95% CI 95% confidence interval, Vx% percentage of tissue volume encompassed by the x% isodose line, Dx% dose to x% of the volume of the
organ at risk, *Paired t-test, n.s. Not significant, other abbreviations: see Table 1.
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last beams was used for the 7 F-IMRT plan with an angle
separation of around 20° and avoiding normal incidence
entry angles (Figure 3). For all techniques, plans were de-
veloped to deliver 95% of the prescribed dose to the full
PTV, and to minimize dose to the OARs lung and heart.
A typical dose distribution for 3D-CRT versus TB-TMRT
and TB-IMRT versus 7 F-IMRT is demonstrated in
Figure 4.
Statistical analysis
Per patient, in vivo GafChromic film dosimetry readings
were obtained at three defined positions (central, medial,
lateral) of the PTV (whole breast or chest wall) during
the use of two radiotherapy techniques (first patient
series, 3D-CRT followed by TB-IMRT; second patient
series, TB-IMRT followed by 7 F-IMRT). The mean dose
in vivo GafChromic film dose measurements obtained at
three consecutive treatment fractions was used for the
statistical analysis (Table 1).
The paired t-test was used to assess the difference of
in vivo GafChromic film readings or calculated plan pa-
rameters of the compared pairs of radiation techniques
for statistical significance. Differences were considered
statistically significant if the two-sided p-value was less
than or equal 0.05.
The Pearson correlation coefficient was calculated to
assess the degree of association between the in vivo Gaf-
Chromic film dosimetry readings in the central, medial
or lateral position of the PTV and the calculated skin
dose derived from DVHs.
Results
In vivo GafChromic film dosimetry measurements and
calculated plan parameters comparing two radiotherapy
techniques in the same patient were obtained of 45 un-
selected breast cancer patients (Table 1).
Table 3 demonstrates that 7 F-IMRT significantly
reduced the in vivo GafChromic film dosimetry read-
ings in the central and lateral film position of the
PTV compared to TB-IMRT. No significant difference of
the in vivo GafChromic film dosimetry readings was
found between 3D-CRT and TB-IMRT. A correspondingobservation was made for the calculated skin dose derived
from DVHs.
The correlation analysis revealed a week but statisti-
cally significant correlation between the calculated skin
dose and the in vivo GafChromic film dosimetry readings
in the central (r = 0.39; p = 0.01), medial (r = 0.28; p = 0.02)
and lateral (r = 0.35; p < 0.01) film position of the PTV.
Comparison of plan parameters revealed a significantly
improved CI and significantly reduced dose to the left
heart and ipsilateral lung of TB-IMRT plans compared
to 3D-CRT plans (Table 4). As expected, 7 F-IMRT
plans exhibited a significantly increased heart and lung
dose compared to TB-IMRT plans due to the multiple
beam angles used. No significant difference concerning
the CI and HI was observed between the 7 F-IMRT and
corresponding TB-IMRT plans. It should be noted that
patients treated with 7 F-IMRT were unselected con-
cerning the thorax or cardiac geometry in this study.
Discussion
The unique feature of our study is that patients were treated
with a treatment plan using two radiation techniques (3D-
CRT and TB-IMRT or TB-IMRT and 7 F-IMRT), and that
the resulting superficial doses of the compared pairs of
radiotherapy techniques were evaluated in the same patient.
The advantage of this study design is that possible factors
influencing the superficial dose (for example factors re-
lated to the patient set-up) are minimized and therefore
observed differences are most probably related to the dif-
ferent radiation techniques.
Our in vivo GafChromic film dosimetry data show that
7 F-IMRT significantly reduces the surface dose compared
to TB-IMRT or 3D-CRT in the adjuvant radiotherapy of
breast cancer. A corresponding observation was obtained
for the calculated skin dose derived from DVHs.
Our results are in excellent agreement with a film-
based phantom study using an anthropomorphic female
thorax phantom and GafChromic films for the dose
measurements [19]. In agreement with our study, tan-
gential irradiation resulted in surface doses mainly
within 45–65% of the target dose (our study: 40-60%).
7 F-IMRT significantly reduced the surface dose com-
pared to TB-IMRT or 3D-CRT. In the central beam axis
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(approximately 15%; our study: 15.6%). Furthermore, no
significant difference or only small differences were ob-
served between 3D-CRT and TB-IMRT in both studies.
It should be noted that the dose at the effective meas-
urement depth of cells associated with acute skin reac-
tion has been estimated to be approximately 15%
below the surface dose measured by in vivo GafChro-
mic film dosimetry [20].
There are also differences in the results of the phan-
tom study and our study. In the phantom study, the
greatest dose reduction was located in the regions clos-
est to the medial and lateral field borders whereas in our
study the greatest dose reduction was observed at the
central and lateral beam region. This finding may be due
to differences in the PTV and treatment set-up between
the phantom and breast cancer patients.
However, the advantage of in vivo GafChromic film
dosimetry compared to phantom studies is that in vivo
measurements potentially more reliably reflect the clin-
ical treatment situation with its uncertainties of patient
positioning variability, breathing motion, and variability
of the body geometry.
In agreement with the literature, comparison of calcu-
lated plan parameters showed an advantage of TB-IMRT
compared to 3D-CRT concerning the CI, heart dose in
patients with left-sided breast cancer and ipsilateral lung
dose [6,7,21]. As expected, due to the multiple beam an-
gles used, 7 F-IMRT showed a higher low-dose volume
to the heart, ipsilateral and contralateral lung compared
to TB-IMRT [22].
Thorough characterization of differences of the dose
distribution is important to select the most appropriate
radiation technique for the individual patient. For se-
lected left-sided breast cancer patients with unfavorable
thorax or cardiac geometry, multifield IMRT has been
shown to be able to dramatically reduce the high-dose
volume of the heart compared to 3D-CRT [4,5]. Multi-
field IMRT most probably reduces the risk of severe late
heart toxicity and may therefore be the preferred radi-
ation technique in these selected patients. In our study,
unselected patients concerning the thorax or cardiac
geometry were examined, and no significant sparing of
the high-dose volume of the heart was observed. How-
ever, our data show that 7 F-IMRT is able to signifi-
cantly reduce the superficial dose compared to TB-IMRT
or 3D-CRT. Due to the multiple beam angles used,
7 F-IMRT is associated with a considerably larger low-
dose volume to the heart and lungs compared to TB-IMRT
or 3D-CRT. The advantage of a reduced risk of radiation
skin reactions with 7 F-IMRT has to be balanced with the
potentially increased risk of heart and lung toxicity. This
applies especially to patients with left-sided breast cancer.
Large breast size is significantly associated with an increasedrisk of radiation reactions of the skin [9,23]. For patients
with large breasts 7 F-IMRT may be considered to reduce
severe skin toxicity and to improve cosmetic results in
particular in patients with right-sided breast cancer. In
patients with inflammatory breast cancer where tumor
cells are located in the skin, 7 F-IMRT may not be the
preferred radiation technique due to the reduced superficial
dose compared to TB-IMRT or 3D-CRT.
In conclusion, our data suggest that in radiotherapy of
the breast or chest wall, 7 F-IMRT offers a significantly re-
duced surface dose compared to TB-IMRT or 3D-CRT.
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